Placentalia

Pluri’s PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation

Retrieved on: 
Wednesday, August 16, 2023

As described in the article, in a successful Phase I first-in-human study which achieved its primary endpoint, patients with incomplete hematopoietic recovery post-hematopoietic cell transplantation (HCT) were treated with escalating doses of Pluri’s cell therapy, PLX-R18.

Key Points: 
  • As described in the article, in a successful Phase I first-in-human study which achieved its primary endpoint, patients with incomplete hematopoietic recovery post-hematopoietic cell transplantation (HCT) were treated with escalating doses of Pluri’s cell therapy, PLX-R18.
  • Low levels of blood cells (cytopenia) post-HCT can persist despite adequate engraftment of donor cells.
  • Pluri’s PLX-R18 cells secrete a large array of hematopoietic factors which promote regeneration, maturation, and differentiation of hematopoietic cells and stimulate their migration to peripheral blood.
  • As a groundbreaking, first-in-class solution, PLX-R18’s capacity to augment hematopoietic system recovery and effectively manage diverse cytopenia holds immense promise.”

Investigating the placenta: Discovery from Stowers Scientists shows why this often-overlooked organ should be given more attention

Retrieved on: 
Wednesday, June 7, 2023

"I feel like generally as scientists and as a society, we're simply not giving the placenta its due consideration."

Key Points: 
  • "I feel like generally as scientists and as a society, we're simply not giving the placenta its due consideration."
  • "Following birth, the placenta is often tossed in the medical wastebin," explained Stowers Investigator Jennifer Gerton, Ph.D. "This makes it the most overlooked, undervalued, and understudied organ in reproductive science."
  • "The placenta may be the most polyploid organ in a pregnant female mouse, but more research into polyploidy is warranted."
  • "I feel like generally as scientists and as a society, we're simply not giving the placenta its due consideration."

TEZSPIRE® APPROVED FOR SELF-ADMINISTRATION IN THE U.S. WITH A NEW PRE-FILLED PEN

Retrieved on: 
Thursday, February 2, 2023

THOUSAND OAKS, Calif., Feb. 2, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE® (tezepelumab-ekko) for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.1 First approved by the FDA in December 2021, TEZSPIRE is the only biologic approved for severe asthma with no phenotype (e.g., eosinophilic or allergic) or biomarker limitation within its approved label.2-9

Key Points: 
  • "We believe self-administration alternatives can play an important role in patients' lives and address unmet needs for those living with severe asthma."
  • TEZSPIRE is currently approved for the treatment of severe asthma in the U.S., EU, Japan and other countries.
  • TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
  • Hypersensitivity reactions were observed in the clinical trials (e.g., rash and allergic conjunctivitis) following the administration of TEZSPIRE.

TEZSPIRE™ (TEZEPELUMAB-EKKO) NOW AVAILABLE IN THE UNITED STATES FOR THE TREATMENT OF SEVERE ASTHMA

Retrieved on: 
Thursday, January 13, 2022

The Tezspire Together Program offers provider and patient product resources and support, including information related to coverage, reimbursement and distribution.

Key Points: 
  • The Tezspire Together Program offers provider and patient product resources and support, including information related to coverage, reimbursement and distribution.
  • TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
  • TEZSPIRE should not be used to treat acute asthma symptoms, acute exacerbations, acute bronchospasm, or status asthmaticus.
  • If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.

TEZSPIRE Now Available in the United States for the Treatment of Severe Asthma

Retrieved on: 
Thursday, January 13, 2022

With TEZSPIRE now available, this important new treatment has the potential to transform care for a broad population of patients living with severe asthma.

Key Points: 
  • With TEZSPIRE now available, this important new treatment has the potential to transform care for a broad population of patients living with severe asthma.
  • TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
  • If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.
  • The management of severe asthma: economic analysis of the cost of treatments for severe asthma.

TEZSPIRE (tezepelumab) Approved in the US for Severe Asthma

Retrieved on: 
Friday, December 17, 2021

TEZSPIRE represents a much-needed new treatment for the many patients who remain underserved and continue to struggle with severe, uncontrolled asthma.

Key Points: 
  • TEZSPIRE represents a much-needed new treatment for the many patients who remain underserved and continue to struggle with severe, uncontrolled asthma.
  • TEZSPIRE is a first-in-class medicine indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
  • If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.
  • The management of severe asthma: economic analysis of the cost of treatments for severe asthma.

FDA APPROVES TEZSPIRE™ (TEZEPELUMAB-EKKO) IN THE U.S. FOR SEVERE ASTHMA

Retrieved on: 
Friday, December 17, 2021

"Tezspire represents a much-needed new treatment for the many patients who remain underserved and continue to struggle with severe, uncontrolled asthma."

Key Points: 
  • "Tezspire represents a much-needed new treatment for the many patients who remain underserved and continue to struggle with severe, uncontrolled asthma."
  • "For the first time, many people living with severe asthma have the opportunity to receive treatment regardless of the cause of their inflammation."
  • Tezspireis a first-in-class medicine indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
  • If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.

Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Fall 2021 Conference

Retrieved on: 
Wednesday, October 27, 2021

Anthony Benedetto, DO, FACP, founder and medical director of the Dermatologic SurgiCenter in Philadelphia, will present his experience using dermal substitutes in Post-Mohs surgeries and post-surgery wound care.

Key Points: 
  • Anthony Benedetto, DO, FACP, founder and medical director of the Dermatologic SurgiCenter in Philadelphia, will present his experience using dermal substitutes in Post-Mohs surgeries and post-surgery wound care.
  • Attendees are encouraged to visit the Organogenesis exhibit hall booth (#501) to learn more about the latest advanced wound care products and latest studies.
  • Featuring a dual-edge adjustable blade, built-in ruler and contoured grip, this new product aims to elevate the standard of care for wound debridement.
  • Organogenesis cautions investors not to place undue reliance on the forward-looking statements contained in this release.